Combining hepatic surface nodularity and serum tests better predicts hepatic fibrosis stages in chronic liver disease.

Hepatic surface nodularity combined with serum blood test could be a practical method to predict cirrhosis, advanced fibrosis, and significant fibrosis in chronic liver disease patients, providing higher accuracy than using serum fibrosis indices alone.